FN1 and neoplasm: TN-C has been reported to compete with the binding site of fibronectin with syndecan-4, and this interaction with syndecan-4 partially abrogates the effects of this co-receptor, as well as attenuates the interaction of syndecan-4 with fibronectin, enhancing tumor cell malignancy.